CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,912 enrolled
Drug / intervention
ClearGuard HD end capdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02604264
NCT02604264N/ACompleted
CompareCT.gov

Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

Pursuit Vascular, Inc.·interventional·Posted Nov 13, 2015·Updated Sep 11, 2018

In Brief

A clinical study evaluating ClearGuard HD end cap for End Stage Renal Disease (ESRD). Completed, enrolled 2,912 participants across 1 site.

Detailed Summary

To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease (ESRD)
CountriesUnited States
CollaboratorsFresenius Medical Care North America

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 13, 2015
Enrollment StartDec 1, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.6 years ago

Interventions

ClearGuard HD end capdevice

The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub